Amylyx Pharmaceuticals annual revenue
2021
2022
2023
2024
2025
Amylyx Pharmaceuticals Revenue Growth & History (AMLX)
Amylyx Pharmaceuticals reported $0 in revenue for fiscal 2025, a decrease of 100.00% from the previous fiscal year.
View full Amylyx Pharmaceuticals company overviewAmylyx Pharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0 | −$87.4M | −100.00% |
| 2024 | 2024-12-31 | $87.4M | −$293.4M | −77.06% |
| 2023 | 2023-12-31 | $380.8M | $358.6M | +1612.94% |
| 2022 | 2022-12-31 | $22.2M | $21.9M | +7700.00% |
| 2021 | 2021-12-31 | $285,000 | — | — |
Amylyx Pharmaceuticals quarterly revenue
Q3.21
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | $0 | — |
| Q1 2026 | 2026-03-31 | $0 | $0 | — |
| Q4 2025 | 2025-12-31 | $0 | $665,000 | +100.00% |
| Q3 2025 | 2025-09-30 | $0 | −$416,000 | −100.00% |
| Q2 2025 | 2025-06-30 | $0 | $1.0M | +100.00% |
| Q1 2025 | 2025-03-31 | $0 | −$88.6M | −100.00% |
| Q4 2024 | 2024-12-31 | −$665,000 | −$109.1M | −100.61% |
| Q3 2024 | 2024-09-30 | $416,000 | −$102.3M | −99.59% |
| Q2 2024 | 2024-06-30 | −$1.0M | −$99.2M | −101.04% |
| Q1 2024 | 2024-03-31 | $88.6M | $17.2M | +24.10% |
| Q4 2023 | 2023-12-31 | $108.4M | — | — |
| Q3 2023 | 2023-09-30 | $102.7M | $102.3M | +29666.09% |
| Q2 2023 | 2023-06-30 | $98.2M | — | — |
| Q1 2023 | 2023-03-31 | $71.4M | — | — |
| Q3 2022 | 2022-09-30 | $345,000 | $60,000 | +21.05% |
| Q3 2021 | 2021-09-30 | $285,000 | — | — |
Amylyx Pharmaceuticals revenue growth trends
Amylyx Pharmaceuticals's latest reported quarter, Q2 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Amylyx Pharmaceuticals source filings ↗